Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Our Executive Vice President of Scientific Affairs, Dr. Lynn Webster, has released a co-authored review on opioid abuse-deterrent formulations (ADFs). This comprehensive analysis delves into the effectiveness of ADFs in reducing misuse and abuse while highlighting the significant barriers to access that hinder effective opioid treatment. Discover the latest insights and understand the critical challenges in our fight against the opioid crisis.

Key points covered:

  • Pain Management and Risk of OUD
  • Role of Abuse Deterrent Formulations in Reducing Abuse and Misuse
  • Manipulation Methods
  • Prescriber and Insurance Perspective

Lynn Webster, MD

Executive Vice President, Scientific Affairs

Dr. Webster is an internationally recognized clinical research expert in pain and addiction medicine. He has participated as an Investigator in hundreds of clinical trials and has authored more than 300 peer reviewed articles. He is board certified in anesthesiology, pain medicine and addiction medicine. He is the former co-founder of Lifetree Medical as well as an editor of Pain Medicine. Dr. Webster also serves as a peer reviewer of several professional journals and is a National Institute of Health grant reviewer. He has significant expertise in clinical research with a focus in experimental and human pain models, human abuse potential studies as well as assessing drugs’ effects on respiratory depression.

Interested in conducting a clinical trial?